Pfizer and BioNTech start trial of Omicron-targeted vaccine

Top of the morning to you, and a superb one it’s. Though grey skies are hovering over the Pharmalot campus, our spirits stay sunny as a result of, because the Morning Mayor taught us, “Each model new day ought to be unwrapped like a valuable reward.” We provide this reminder to people who might stay apprehensive about what lies forward. In the meantime, there may be work to be carried out. So time to get on with it and seize a cup of stimulation — our alternative as we speak is blueberry mountain. As all the time, be happy to hitch us. And now, listed below are some gadgets of curiosity. Hope your day is manageable, and do keep in contact. …

Pfizer (PFE) and BioNTech (BNTX) have began a trial evaluating an tailored model of their Covid-19 vaccine concentrating on the Omicron variant of the coronavirus, The Wall Street Journal writes. The drug makers started enrolling adults ages 18 to 55 within the U.S. and South Africa to look at security and tolerability and the immune response generated by the vaccine whether it is given both as a major sequence or as a booster dose. Preliminary examine outcomes are anticipated within the first half of the yr, and Pfizer may ask U.S. regulators for authorization and start distribution in March. Nevertheless, STAT notes it’s unclear what knowledge regulators will need earlier than authorizing use.